NORVIR Drug Patent Profile

When do Norvir patents expire, and when can generic versions of Norvir launch?

Norvir is a drug marketed by Abbott and Abbvie and is included in five NDAs.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Norvir

A generic version of NORVIR was approved as ritonavir by CIPLA on January 15^th, 2015.

Summary for NORVIR

US Patents:	0
Applicants:	2
NDAs:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Patent Applications:	2,657
Drug Prices:	Drug price information for NORVIR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NORVIR
What excipients (inactive ingredients) are in NORVIR?	NORVIR excipients list
DailyMed Link:	NORVIR at DailyMed

See drug prices for NORVIR

Recent Clinical Trials for NORVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pyramid Biosciences	Phase 1
Pardes Biosciences, Inc.	Phase 1
Soroka University Medical Center	Phase 3

See all NORVIR clinical trials

Pharmacology for NORVIR

Drug Class	Cytochrome P450 3A Inhibitor Protease Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

Paragraph IV (Patent) Challenges for NORVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NORVIR	Tablets	ritonavir	100 mg	022417	1	2010-12-21

US Patents and Regulatory Information for NORVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	NORVIR	ritonavir	CAPSULE;ORAL	020680-001	Mar 1, 1996		DISCN	No	No
Abbvie	NORVIR	ritonavir	SOLUTION;ORAL	020659-001	Mar 1, 1996		DISCN	Yes	No
Abbvie	NORVIR	ritonavir	CAPSULE;ORAL	020945-001	Jun 29, 1999		DISCN	Yes	No
Abbvie	NORVIR	ritonavir	POWDER;ORAL	209512-001	Jun 7, 2017		RX	Yes	Yes
Abbvie	NORVIR	ritonavir	TABLET;ORAL	022417-001	Feb 10, 2010	AB	RX	Yes	No

EU/EMA Drug Approvals for NORVIR

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan S.A.S	Ritonavir Mylan	ritonavir	EMEA/H/C/004549Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older).	Authorised	yes	no	no	2017-11-09
AbbVie Deutschland GmbH Co. KG	Norvir	ritonavir	EMEA/H/C/000127Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients (adults and children of two years of age and older).	Authorised	no	no	no	1996-08-25

International Patents for NORVIR

See the table below for patents covering NORVIR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	210441
Australia	1524895
Australia	700942
Canada	2178632	COMPOSITIONS PHARMACEUTIQUES CONTENANT DES INHIBITEURS DE PROTEASE DU VIH (PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS)
Canada	2540258
Germany	69524567
Denmark	0732923

Supplementary Protection Certificates for NORVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0674513	C00674513	Switzerland		PRODUCT NAME: LOPINAVIR UND RITONAVIR; REGISTRATION NO/DATE: IKS 55648 20001213
0674513	SPC/GB01/044	United Kingdom		PRODUCT NAME: THE COMBINATION OF THE ACTIVE INGREDIENTS RITONAVIR AND LOPINAVIR; REGISTERED: CH 55649 20001213; UK EU/1/01/172/001 20010320; UK EU/1/01/172/002 20010320; UK EU/1/01/172/003 20010320
0674513	C300060	Netherlands		PRODUCT NAME: RITONAVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF EEN FARMACEUTISCH AANVAARDBARE ESTER, EN LOPINAVIR; REGISTRATION NO/DATE: EU/1/01/172/001 - EU/1/01/172/003 20010320

Norvir (ritonavir) Market Dynamics and Financial Trajectory: Exclusivity, Competition, Pricing, and Revenue Outlook

Last updated: July 21, 2026

Norvir (ritonavir) remains a small but strategically important HIV protease-inhibitor franchise in the US and key ex-US markets, with revenue driven by continued antiretroviral regimens that still use ritonavir “boosting” despite broad shift toward non-boosted and newer classes. Near-term financial performance depends more on prescribing inertia and guideline positioning than on new product launches, with generic and segment substitution pressures shaping the sales ceiling.

---

What is Norvir (ritonavir) used for, and how does that drive demand?

Quick answer: Demand is anchored in HIV treatment practice where ritonavir is used as a pharmacokinetic booster (“ritonavir-boosted protease inhibitors”) and, secondarily, in combination ART strategies that still incorporate boosted regimens.

Core indications and where Norvir fits in HIV therapy

• Ritonavir is historically a protease inhibitor and also a booster that increases exposure of co-administered protease inhibitors.
• In modern ART, booster use remains relevant for certain protease inhibitors and for treatment optimization in patients with resistance or regimen constraints.

Real-world demand drivers

1. Guideline persistence of ritonavir-boosted regimens
   Even as integrase inhibitor-based regimens dominate, boosted protease inhibitor strategies remain in use for subsets of patients.
2. Switch frequency and regimen durability
   Patients with established virologic suppression on stable regimens often switch less frequently, sustaining demand.
3. Resistance and comorbidity profiles
   Limited regimen options in resistance scenarios can maintain booster use.
4. Formulary coverage and payer behavior
   Retail and Medicaid managed formularies can preserve usage when ritonavir-boosted options are preferred or cost-neutral.

---

How have Norvir sales performed financially in the past five years?

Quick answer: Historical performance has been stable-to-declining relative to peak HIV-era revenues, with more recent results reflecting the broader ART shift away from protease inhibitors toward integrase inhibitor backbones and increased generic penetration.

Revenue trajectory pattern (typical for legacy HIV boosters)

• Peak-to-decline occurred as ART standards moved to regimens with fewer dosing limitations.
• Plateau has occurred as boosters remain required for specific co-therapies and switching rates are not immediate.
• Ongoing erosion continues as prescribers and payers favor simpler regimens and lower pill burdens.

What moves the needle quarter to quarter

• Volume changes from prescribing mix shifts.
• ASP and rebate dynamics once generics and authorized generics anchor pricing.
• Supply and manufacturing stability for oral liquids and tablets (liquid formulations often matter in pediatric and dosing-flexibility scenarios).

---

What is the Orange Book status of Norvir, and how does it affect pricing and competition?

Quick answer: Norvir’s branded market position is constrained by generic availability and the structure of patent and exclusivity expirations typical for a long-established small-molecule HIV drug. That forces pricing compression and shifts value from brand pricing to supply-chain and contracting leverage.

Generic entry pressure: why it matters for Norvir economics

• Once generics are entrenched, branded revenue tends to track:
  • discounting to maintain contracts,
  • channel mix (institutional vs retail),
  • payer-specific preferred generic lists,
  • and any remaining formulation or method-of-use differentiation.

Practical implications for financial trajectory

• Revenue is more sensitive to:
  • contract losses (rebate pressure),
  • tender wins (institutional buyers),
  • and dispensing dynamics by package size and dosage form.
• Margin profile is typically constrained because brand-led pricing power is limited.

---

When does Norvir lose exclusivity, and how many patents affect the competitive landscape?

Quick answer: For Norvir, exclusivity and patent protection are not the principal determinant of near-term market competition; generics and authorized generics have already defined the competitive baseline for most buying decisions.

Patent estate mechanics that shape market outcomes

• For a legacy drug, patent estates usually influence:
  • specific formulations (e.g., oral liquid attributes),
  • manufacturing processes,
  • and narrow method-of-use or dosing strategies.
• The market impact of remaining late-life patents is often limited unless they block a formulation that is important for dosing populations (pediatrics, tolerability, adherence).

Litigation and Paragraph IV risk relevance

• If any barriers remain, they typically surface in:
  • oral liquid formulation patent disputes,
  • process patents affecting bioequivalence or stability,
  • or labeling-driven method-of-use claims that intersect with payer coverage.

(High-intent consequence for finance: the market is already structured around generic availability, so remaining legal leverage usually affects only incremental share and can shift timing of contract wins rather than create sustained brand-like exclusivity.)

---

How strong is the patent estate for Norvir compared with other ritonavir-boosted regimens?

Quick answer: Compared with on-patent modern HIV drugs, Norvir’s patent-driven differentiation is limited. The competitive field is dominated by whether payers can source lower-cost ritonavir and whether dosing forms needed by subpopulations (e.g., liquid) are competitively supplied.

Competitive comparisons that matter commercially

• Within boosted PI strategies: ritonavir is a “booster commodity” more than a standalone high-growth asset.
• Against newer ART classes: prescribing shifts reduce total booster usage more than patent barriers increase demand.

---

What generic entry risks exist for Norvir, and what generic launch scenarios could change sales?

Quick answer: Near-term “generic entry risk” is less about first generic launch and more about:

• consolidation of supply among fewer players,
• price competition escalation leading to contract renegotiations,
• and any formulation supply constraints affecting dispensing.

Scenarios that move Norvir financials

1. Price erosion from intensified generic competition
   • Higher number of eligible SKUs in formularies compresses net price.
2. Authorized generic supply stability vs brand substitution
   • Stable supply among generic manufacturers can accelerate switching away from the brand.
3. Shortages or manufacturing disruptions
   • If supply constraints hit preferred generic SKUs, demand can temporarily revert to alternative suppliers, including branded stock.
4. Formulation-specific availability
   • Oral liquid availability is often more sensitive to manufacturing bottlenecks than tablets.

---

How does Norvir compare with other HIV protease inhibitors and boosters on market dynamics?

Quick answer: Ritonavir’s market dynamics differ from stand-alone protease inhibitors because its commercial role is partly additive, boosting other drugs. That makes its demand correlated with persistence of ritonavir-boosted regimens rather than with the protease inhibitor lifecycle alone.

Comparative commercial posture

• Protease inhibitors (stand-alone use): demand depends on regimen preference and substitution by newer classes.
• Ritonavir (booster use): demand persists when boosted PI strategies remain clinically justified, but total ceiling still declines with integrase inhibitor dominance.

Implication for financial trajectory

• Revenue should track the slope of booster-era patient retention rather than new patient starts into boosted regimens.
• Any shift in guidelines that de-emphasizes boosting reduces long-term demand.

---

What financial impacts do pricing, rebate structures, and procurement contracts have on Norvir?

Quick answer: For legacy generics-and-contract-driven products like Norvir, net sales are primarily a function of payer negotiation, rebate pass-through, and procurement placement in institutional formularies.

Net price drivers

• Wholesale acquisition vs net sales spread
  • Rebates, discounts, and chargebacks compress brand or higher-priced channel margins.
• State and federal purchasing behavior
  • Medicaid and large integrated delivery networks can move volume to lowest net-cost suppliers.
• Contract duration and “preferred” designations
  • Once preferred status is lost, re-entry can take procurement cycles.

Margin outlook

• Branded margins typically compress toward generic parity when contract pressure intensifies.
• If a branded manufacturer maintains supply reliability or covers niche formulations, it can still defend some margin even under price pressure.

---

How do FDA regulatory status and labeling influence Norvir demand?

Quick answer: FDA labeling shapes prescribing primarily through regimen role clarity, tolerability expectations, and coadministration guidance with other antiretrovirals.

Regulatory factors that affect commercial use

• Labeling consistency for drug-drug interactions
  Ritonavir is a strong CYP/P-gp interaction agent, which can constrain alternative regimen choices.
• Formulation and administration requirements
  • Oral liquid dosing flexibility influences use in pediatric and adherence-sensitive populations.

---

What does the competitive landscape look like for Norvir in the US vs key ex-US markets?

Quick answer: Competition is structurally similar across major geographies: generic availability anchors pricing, while patient mix and payer procurement determine volume distribution.

Regional dynamics

• US: payer formularies and PBM positioning dominate volume. Net price volatility reflects contracting and generic SKU competition.
• Europe/UK: reimbursement frameworks and tendering influence which manufacturers capture institutional share.
• Emerging markets: procurement programs and access initiatives can sustain volume, but local pricing compression and logistics can limit margin.

Business consequence for revenue planning

• Global revenue depends less on “market growth” and more on:
  • tender outcomes,
  • supplier reliability,
  • and availability of required dosage forms.

---

What are the key financial KPIs to monitor for Norvir going forward?

Quick answer: Track a small set of KPIs that predict net sales more accurately than headline market size.

KPI checklist

• US net sales and gross-to-net spread
• Unit volume trends by dosage form (tablet vs oral liquid)
• Contract wins/losses in institutional and federal channels
• Dispensing share shifts between branded and generic suppliers
• Average net price and rebate intensity
• Supply continuity indicators (backorders, manufacturing interruptions)

---

Key Takeaways

• Norvir’s financial trajectory is structurally tied to ritonavir’s role as a booster in HIV regimens, not to standalone growth.
• Generic competition and contracting economics dominate the net sales ceiling, driving continued pricing pressure.
• The strongest near-term revenue lever is stability of demand in boosted PI patient subsets and procurement positioning, especially for dosage forms needed in sensitive populations.
• Future volatility is more likely to come from contract shifts and supply continuity than from patent-driven exclusivity changes.

---

FAQs

1) Why does Norvir revenue remain despite the shift to integrase inhibitor-based ART?
Ritonavir-boosted protease inhibitor strategies persist for specific clinical scenarios and regimen optimization, and patients can remain on stable boosted regimens for extended periods.

2) Does oral liquid ritonavir have different market dynamics than tablets?
Yes. Oral liquids can be more sensitive to manufacturing capacity, and they often matter for pediatric use and dosing flexibility, which can influence supply-linked revenue swings.

3) What drives Norvir net price in the US more: volume growth or rebate pressure?
Rebate and procurement dynamics typically dominate net price, while volume changes track prescribing and regimen persistence.

4) Can supply disruptions in generic ritonavir increase branded Norvir sales temporarily?
Yes. Shortages or allocation issues among preferred generic SKUs can shift demand to alternative suppliers, including the branded product.

5) What patient population changes would most affect Norvir demand?
A faster shift away from boosted PI regimens and reduced initiation of boosted strategies would lower demand over time, while resistance-driven regimen selection that preserves boosted use would sustain it.

---

References

1. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).